Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about NATR, unsubscribe in one click. Privacy
NATR holds $82.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $505,500/quarter from operations, an estimated runway of 489.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NATR files for a raise →
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NATR and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →